Sorafenib
- PDF / 141,138 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 39 Downloads / 131 Views
1
S
Posterior leukoencephalopathy: case report A 58-year-old man, diagnosed with unresectable multinodular hepatocellular carcinoma in December 2008, started receiving treatment with sorafenib 400mg twice daily [route not stated]. One week later, he developed blurred vision and a headache. He was admitted and sorafenib was withdrawn. After a normal neurological examination a week later, he resumed sorafenib therapy. Five days later, he developed hallucinations, dizziness, sialorrhoea and disturbances to his vision and gait. Tests revealed a BP of 165/100mm Hg and cerebellar defects. He received amlodipine and his BP normalised. His clinical symptoms were consistent with posterior leukoencephalopathy. Sorafenib was discontinued. His symptoms had resolved 5 days later and he started receiving doxorubicin therapy. Author comment: "Use of the Naranjo probability scale indicated a probable relationship between encephalopathy and sorafenib in this patient." Dogan E, et al. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Medical Oncology 27: 1436-1437, No. 4, Dec 2010. Available from: URL: http://dx.doi.org/10.1007/s12032-009-9378-6 803052361 Turkey
0114-9954/10/1346-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 9 Apr 2011 No. 1346
Data Loading...
